Seminars in Nephrology
Volume 29, Issue 3 , Pages 227-238, May 2009

Epidemiology of Hyponatremia

  • Ashish Upadhyay, MD

      Affiliations

    • Renal Section, Boston Medical Center and Boston University School of Medicine, Boston, MA
  • ,
  • Bertrand L. Jaber, MD, MS

      Affiliations

    • Department of Medicine, St. Elizabeth's Medical Center and Tufts University School of Medicine, Boston, MA
  • ,
  • Nicolaos E. Madias, MD

      Affiliations

    • Department of Medicine, St. Elizabeth's Medical Center and Tufts University School of Medicine, Boston, MA
    • Corresponding Author InformationAddress reprint requests to Nicolaos E. Madias, MD, Department of Medicine, St. Elizabeth's Medical Center, 736 Cambridge St, Boston, MA 02135

Summary 

Hyponatremia is the most common electrolyte abnormality encountered in clinical practice with wide-ranging prognostic implications in a variety of conditions. This review summarizes the available literature on the epidemiology of hyponatremia in both hospitalized and ambulatory-based patients. Particular attention is given to hyponatremia in the geriatric population, drug-induced hyponatremia, exercise-associated hyponatremia, and the medical costs of hyponatremia. The frequency and outcomes of hyponatremia in congestive heart failure, cirrhosis, pneumonia, and human immunodeficiency virus infection also are reviewed. Although the knowledge on hyponatremia has expanded in the past few decades, the disorder largely remains an underdiagnosed condition. Substantial additional work is needed to improve the awareness of hyponatremia among medical professionals. The advent of vasopressin-receptor antagonists as a plausible treatment option for some forms of euvolemic and hypervolemic hyponatremia now offers the opportunity to gain further insights into the prognostic impact of hyponatremia and its management in various clinical settings.

Keywords: Hyponatremia, epidemiology, outcomes, incidence, prevalence

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grants from the National Institutes of Health (DK065102 and DK07775 to B.L.J.).

 Dr Madias has served as a consultant to and has received lecture fees from Astellas Pharma US, Inc. (manufacturer of Vaprisol–Conivaptan hydrochloride injection), and has served as a consultant to Sanofi-Aventis (manufacturer of Satavaptan).

PII: S0270-9295(09)00020-5

doi:10.1016/j.semnephrol.2009.03.004

Seminars in Nephrology
Volume 29, Issue 3 , Pages 227-238, May 2009